 |
SAMeAccording to research on the compound, it helps to convert norepinephrine to epinephrine and serotonin to melatonin, helping make creatine, and helping the preservation of glutathione, an important antioxidant. What's also important is that the compound is involved in the formation of myelin, the white sheath surrounding nerve cells and can improve the brain cell membrane fluidity, thus potentially enhancing the function of receptors. Also interesting from anti aging perspective is that in studies, it has been found that brain levels of SAMe in Alzheimer's patients are severely decreased. Some are calling the compound a "daytime melatonin", as the natural synthesis of melatonin during the night is dependent on the synthesis of SAMe during the day. There are also a lot of indications in research that the compound is an effective anti-depressant and has liver protecting qualities, as well as it works for arthritis related problems. SAMe - StudiesMorrison LD, Smith DD and SJ Kish. 1996. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J Neurochem 67: 1328-1331. Loehrer MTF, Angst CP, Haefeli WE, Jordan PP, Ritz R and B Fowler. 1996. Low whole-blood S-adenosylmethionine and correlation between 5- methyltetrahydrofolate and homocysteine in coronary artery disease. Arth Throm Vasc Biol 16: 727-733. Bottiglieri T, Hyland K and EH Reyonlds. The clinical potential of ademetionine (s-adenosylmethionine) in neurological disorders. Drugs 48: 137-152, 1994. Konig B. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med 83(5A): 89-94, 1987. Tavoni A, Vitali C, Bombardieri S and G Pasero. The evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover study. Am J Med 83(5A): 107-110, 1987. Jacobsen S, Danneskiold-Samsoe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol 20: 294-302, 1991. Criconia AM, Araquistain JM, Darrina N, Navajas F and M Bordino. Results of treatment with S-adensyl-L-methionine in patients with major depression and internal illnesses. Curr Ther Res 55: 666-674, 1994. Lo Russo A, Monaco M, Pani A and D Fontanari. Efficacy of S-adenosyl-L- Methionine in relieving psychological distress associated with detoxification in opiate abusers. Curr Ther Res 55:905-13. Grassetto M and A Varotto. Primary fibromyalgia is responsive to S-adenosyl-l-methionine. Curr Ther Res 55:797-806. Berlanga C, Ortega-Soto HA, Ontiveros M and H Senties. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res 44: 257-62, 1992. Taylor KM and PK Randall. Depletion of S-adenosyl-L-methionine in mouse brain by antidepressive drugs. J Pharmacol Exp Ther 194: 303-10, 1975. Hietala OA, Laitinen SI, Laitinen PH, Lapinjoki SP and AE Pajunen. The inverse changes of mouse brain ornithine and S-adenosylmethionine decarboxylase activites by chlorpromazine and imipramine. Dependence of ornithine decarboxylase induction on beta-adrenoceptors. Biochem Pharmacol 32: 1581-5, 1983. Vendemiale G, Altomare E, Trizio T, et al. 1989. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 24: 407-14. Corrales F, Ochoa P, Rivas C, et al. 1991. Inhibition of glutathione synthesis in the liver leads to S-adenosyl-L-methionine synthetase reduction. Hepatol 14: 528-33. Duce AM, Ortiz P, Cabrero C and JM Mato. 1988. S-adenosyl-L-methioninesynthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatol 8: 65-8. Tobena R, Horikawa S, Calvo V and S Alemany. 1996. Interleukin-2 induces gamma-S-adenosyl-L-methionine synthetase gene expression during T-lymphocyte activation. Biochem J 319: 929-33. Diaz Belmont A, Dominguez Henkel R and F Uribe Ancira. 1996. SAMe Parenteral en el tratamiento de la hepatopatia alcoholica comparative contra placebo. Anales de Medicine Inter 13: 9-15. Rafique S, Guardascione M, Osman E, et al. 1992. Reversal of extrahepatic membrane cholesterol deposition in patients with chronic liver diseases by S-adenosyl-L-methioinine. Clin Sci 83: 3535-6. Frezza M, Tritapepe R, Pozzato G and C DiPadova. 1988. Prevention by S-adenosylmethionine of estrogen-induced hepatobiliary toxicity in susceptible women. Am J Gastroenterol 83: 1098-1102. Simile MM, Pascale R, De Miglio MR, et al. 1994. Correlation between S-adenosyl-L-methionine content and production of c-myc, c-Ha-ras, and c-Ki-ras mRNA transcripts in the early stages of rat liver carcinogenesis. Cancer Lett 79: 9-15. Barak AJ, Beckenhauer HC and DJ Tuma. 1994. S-adenosylmethionine generation and prevention of alcoholic fatty liver by betaine. Alcohol 11: 501-3. Gutierrez S, et al. SAMe restores the changes in the proliferation and in the synthesis of fibronectin and proteoglycans induced by tumor necrosis factor alpha on cultured rabbit synovial cells. Brit Rheumatol 37: 27-31, 1997. Osteoarthritis: the clinical picture, pathogenesis and management with studies on a new therapeutic agent, S-adenosylmethionine. Am J Med 83 (Suppl 5A) 1987 (Includes Numerous Studies). Marcolongo R, et al. Double-blind multicentre study of activity of S-adenosylmethionine in hip and knee osteoarthritis. Curr Ther Res 37: 82-94. Tavoni A. et al Evaluation of S-adenosylmethionine in primary fibromyaglia: a double blind crossover study. Am J Med 83 (Suppl 5A): 107-110, 1987. Jacobsen S, et al Oral S-adenosylmethionine in primary fibroyaglia. Double-blind clinical evaluation. Scand J Rheumatol 20: 294-302, 1991.
|